Aircraft Ejection Seats Market Study, Growth Factor, CAGR Fluctuation Probability

Pune, Maharashtra, India, October 27 2020 (Wiredrelease) MarketResearch.Biz :The recently published market study byMarketResearch.Bizhighlights the current and future trends that are expected to influence the dynamics of the Aircraft Ejection Seats Market[1] in the upcoming years. The report introspects the supply chain, cost structure, and recent developments pertaining to the Aircraft Ejection Seats market in the report. Further, the micro...

READ MORE Aircraft Ejection Seats Market Study, Growth Factor, CAGR Fluctuation Probability

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 23, 2020 /PRNewswire/ — Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance®(empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction – with and without diabetes – regardless of chronic kidney disease status at baseline. These results were shared today as an...

READ MORE New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

DANVERS, Mass.–(BUSINESS WIRE[1])–The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella[2]-supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up. The interim analysis was presented today by Mitul Patel, MD, an interventional cardiologist at UC San Diego...

READ MORE Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up) Interim results from Axon Therapies’ First-in-Human Trial of the Satera Ablation System (11 HFpEF patients at 1- and 3-month follow-up) NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing one of the root...

READ MORE Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

Generated by Feedzy